Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

July 31, 2015

Conditions
Kidney Cancer
Interventions
DRUG

sorafenib tosylate

Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy

Trial Locations (1)

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Doris Duke Charitable Foundation

OTHER

collaborator

Bayer

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER